作者: Paul H. Huang , Forest M. White
DOI: 10.1007/978-1-60327-553-8_40
关键词:
摘要: Recent studies have demonstrated that robustness in oncogenic signaling networks is a key contributor of resistance to kinase inhibitor monotherapy glioblastoma patients. In this chapter, we will review several examples where combinatorial inhibition has been employed as means overcome chemoresistance the laboratory setting. Additionally, summarize approaches by which systems-level phosphoproteomic platforms, combination with computational tools, can be develop better therapeutic strategies and translate such discoveries from bench bedside.